Sulfonylurea: Personalized Medicine for Type 2 Diabetes

Sulfonylurea: Personalized Medicine for Type 2 Diabetes

Bibliographic Details
Main Author:	You-Cheol Hwang
Format:	Article
Language:	English
Published:	Academya Publishing Co. 2015-12-01
Series:	Endocrinology and Metabolism
Online Access:	http://e-enm.org/Synapse/Data/PDFData/2008ENM/enm-30-467.pdf

Similar Items

Sulfonylureas and cardiovascular complications of type 2 diabetes mellitus
by: Lyudmila Viktorovna Nedosugova
Published: (2013-06-01)

Sulfonylureas in the modern strategy of therapy of type 2 diabetes
by: Lyudmila Viktorovna Nedosugova
Published: (2011-06-01)

Consensus recommendations on sulfonylurea & sulfonylurea combinations in the management of Type 2 diabetes mellitus - international task force
by: Sanjay Kalra, et al.
Published: (2019-01-01)

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Commentary on “Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of type 2 diabetes mellitus: International Task Force”
by: S K Singh
Published: (2018-01-01)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
by: Se Hee Min, et al.
Published: (2015-12-01)

Rational Prescribing of Sulfonylurea in Patients with Diabetes Mellitus Type 2
by: V.I. Pankiv
Published: (2012-04-01)

Pharmacogenetic testing in the treatment of type 2 diabetes with sulfonylurea drugs
by: G. I. Gorodetskaya, et al.
Published: (2018-02-01)

The association of Sulfonylurea receptor 1 and Kir6.2gene polymorphism with the treatment of Sulfonylurea and Biguanide in the type 2 diabetes mellitus patients
by: Shieh-Yang Huang, et al.
Published: (2007)

Pharmacoeconomic aspects of the use of sulfonylurea drugs in type 2 diabetes mellitus
by: Alla Vsevolodovna Rudakova
Published: (2011-09-01)

Sulfonylureas in type 2 diabetes mellitus: Current evidence, conflicts and clinical implications
by: Chiedozie Kenneth Ugwoke, et al.
Published: (2017-01-01)

Comparison of different sulfonylureas in type 2 diabetes mellitus with ischemic heart disease
by: Ta-Ting Huang, et al.
Published: (2009)

Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
by: Yeoree Yang, et al.
Published: (2016-10-01)

<it>TCF7L2 </it>and therapeutic response to sulfonylureas in patients with type 2 diabetes
by: Stumvoll Michael, et al.
Published: (2011-02-01)

The effect of combination therapy of sulfonylurea, metformin, and acarbose in type 2 diabetes mellitus patients
by: Tri Murti Andayani,, et al.
Published: (2009-12-01)

The place of the third generation sulfonylurea glimepiride in modern therapy of type 2 diabetes mellitus
by: L.V. Zhuravlyova, et al.
Published: (2019-03-01)

Starting with low dose sulfonylurea and metformin in early stage type 2 diabetes mellitus
by: Joe George
Published: (2015-01-01)

Effect of genetic polymorphisms on the development of secondary failure to sulfonylurea in Egyptian patients with type 2 diabetes
by: Alaa E. El-sisi, et al.
Published: (2011-08-01)

Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement
by: Sanjay Kalra, et al.
Published: (2015-01-01)

Antidiabetic Effects of Add-On Gynostemma pentaphyllum Extract Therapy with Sulfonylureas in Type 2 Diabetic Patients
by: V. T. T. Huyen, et al.
Published: (2012-01-01)

Diabetes Mellitus Type 2: Choice of Sulfonylurea Preparation Taking into Account Patient’s Eating Behavior
by: V.I. Pankiv
Published: (2013-09-01)

Evaluation of different sulfonylureas in type 2 diabetes mellitus with severe hypoglycemia leading to hospital admission
by: Ling Chien Hsu, et al.
Published: (2010)

Efficacy and safety of adding sitagliptin in patients with type 2 diabetes mellitus controlled on metformin and sulfonylureas
by: Pei-Ching Chien, et al.
Published: (2012)

Withdrawal of sulfonylureas from patients with type 2 diabetes receiving long-term sulfonylurea and insulin combination therapy results in deterioration of glycemic control: a randomized controlled trial
by: Srivanichakorn W, et al.
Published: (2015-03-01)

Treatment progression in sulfonylurea and dipeptidyl peptidase-4-inhibitor cohorts of type 2 diabetes patients on metformin
by: Peng X, et al.
Published: (2016-08-01)

The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy
by: Saberi M, et al.
Published: (2020-06-01)

Evaluation of cardiovascular risk associated with specificity of sulfonylureas to the mitochondrial potassium channels in type 2 diabetic patients
by: HUANG, YA-LING, et al.
Published: (2019)

Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact
by: Antoni Sicras-Mainar, et al.
Published: (2014-12-01)

Diabetes mellitus in the young: Gliptins or sulfonylurea after metformin?
by: J Muthukrishnan, et al.
Published: (2012-01-01)

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: A randomized controlled trial (the RECORD study)
by: Zambanini Andrew, et al.
Published: (2008-04-01)

A novel approach to support evidence-based medicine: should sulfonylureas remain an acceptable therapy for diabetes?
by: Powell, Ryan
Published: (2017)

Transcription factor 7-like 2 rs7903146 polymorphism and therapeutic response to sulfonylureas in patients with type 2 diabetes
by: Ghada A Omar, et al.
Published: (2018-01-01)

Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial
by: Seung-Eun Lee, et al.
Published: (2019-08-01)

Evaluation of the efficiency and safety of therapy with a combination of sulfonylurea derivatives and insulin sensitizers for type 2 diabetes mellitus
by: O N Goncharenko, et al.
Published: (2012-08-01)

Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea
by: Sung-Chen Liu, et al.
Published: (2012)

Sulfonylureas: Asset or liability?
by: Om J Lakhani, et al.
Published: (2015-01-01)

Pharmacoepidemiology Study on Cardiovascular Risk in Type Ⅱ Diabetes Mellitus Patients Exposed to Different Sulfonylureas
by: Pin-Zi Chen, et al.
Published: (2010)

Enlarged glycemic variability in sulfonylurea-treated well-controlled type 2 diabetics identified using continuous glucose monitoring
by: Fumi Uemura, et al.
Published: (2021-03-01)

Comparison of antidiabetic drugs added to sulfonylurea monotherapy in patients with type 2 diabetes mellitus: A network meta-analysis.
by: Dan Qian, et al.
Published: (2018-01-01)

Gliclazide and bedtime insulin are more efficient than insulin alone for type 2 diabetic patients with sulfonylurea secondary failure
by: Chazan A.C.S., et al.
Published: (2001-01-01)

Cannot write session to /tmp/vufind_sessions/sess_81fvojrvps6avrlqsgb741ahsa